Iloperidone for the treatment of schizophrenia
First Claim
1. A method of treating schizophrenia or a symptom of schizophrenia in an individual, the method comprising:
- administering to the individual a titrated first daily dose of 16-24 mg/day of iloperidone or a pharmaceutically-acceptable salt thereof during an acute treatment phase, wherein the acute treatment phase follows an initial titration of iloperidone,followed by administering to the individual a second daily dose that is smaller than the titrated first daily dose and is 12-16 mg/day of iloperidone or a pharmaceutically-acceptable salt thereof during a maintenance treatment phase, following completion of the acute treatment phase.
2 Assignments
0 Petitions
Accused Products
Abstract
Aspects of the invention relate generally to the treatment of schizophrenia in an individual and, more specifically, to the treatment of an individual with iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof. In one embodiment, the invention provides a method of preventing schizophrenic relapse in an individual diagnosed with schizophrenia, the method comprising: administering to the individual iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof at a daily dose between about 12 mg and about 16 mg following a period in which the individual'"'"'s schizophrenia was stabilized.
2 Citations
20 Claims
-
1. A method of treating schizophrenia or a symptom of schizophrenia in an individual, the method comprising:
-
administering to the individual a titrated first daily dose of 16-24 mg/day of iloperidone or a pharmaceutically-acceptable salt thereof during an acute treatment phase, wherein the acute treatment phase follows an initial titration of iloperidone, followed by administering to the individual a second daily dose that is smaller than the titrated first daily dose and is 12-16 mg/day of iloperidone or a pharmaceutically-acceptable salt thereof during a maintenance treatment phase, following completion of the acute treatment phase. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
-
12. A method of continuing the treatment of schizophrenia in an individual who has been receiving a titrated first daily dose of 16-24 mg/day of iloperidone or a pharmaceutically acceptable salt thereof during an acute treatment phase of the schizophrenia, the method comprising:
administering a second daily dose of 12-16 mg/day of iloperidone or the pharmaceutically acceptable salt thereof that is reduced relative to the first daily dose during a subsequent maintenance treatment phase following completion of the acute treatment phase. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20)
Specification